Cultural alignment and trust are paramount considerations when exploring collaborations or investments in the Chinese biotech sector
In Conversation
We need partners who understand that our mission is more than a business
After so many years of globalization, it is clear that we are interdependent and interconnected. Cutting off the channels of cooperation would lead to harm on…
Our dedication to advancing technology and making tangible differences in healthcare is unwavering. Partnering with Jacobio Pharmaceuticals offers a unique opportunity to collaborate on groundbreaking initiatives…
Our aim is not to become as large as the IQVIAs or Parexels of this world, but to remain a mid-sized CRO that is as global…
We want to be the prime example of an innovative, science-driven biotech from China, showcasing the best of world capability in terms of innovation, rather than…
Our intention is to become a China-based international company that leads in the genomics space globally
BioDuro has very strong capabilities on the discovery side and has a significant presence in both China and the US. Meanwhile, Sundia is extremely strong in…
The traditional bulk analysis method is well-established and suited for diseases that are more homogenous, but cancer and some types of autoimmune diseases are well-known for…
Despite the fact that I joined the company during the peak of the COVID-19 epidemic in China, we have achieved a number of milestones in the…
We believe, to make a meaningful impact on treatment, it is necessary to have more than one drug or regimen. We therefore see combination therapies as…
Unmet medical needs in eye care are huge in the Asia markets, and biotech companies will become increasingly important players and innovation drivers in this area
